SlideShare a Scribd company logo
Dental Biochemistry 1- (4)
Enzymes, coenzymes,
cofactors
1
Enzymes
• Almost all enzymes are proteins.
• Enzymes follow the physical and chemical
reactions of proteins.
• They are heat labile, soluble in water,
precipitated by protein precipitating
reagents (ammonium sulfate or
trichloroacetic acid) and contain 16%
weight as nitrogen.
2
Enzymes are biocatalysts
• Catalysts are substances which accelerate the
rate of chemical reactions, but do not change
the equilibrium.
• Lack of enzymes will lead to block in
metabolic pathways causing inborn errors of
metabolism.
• The substance upon which an enzyme acts, is
called the substrate.
• The enzyme will convert the substrate into the
product or products.3
Nomenclature of enzymes
• Early workers gave whimsical names such as
Pepsin, Trypsin, Chymotrypsin, ….etc.
• Later workers gave the trivial names for some
enzymes named by adding the suffix "ase" to
the substrate, as example, enzyme Lactase
acts on the substrate lactose.
• But there may be more than one enzyme
acting on the same substrate.4
Classification of enzymes
According to its function
• Class 1. Oxidoreductase:
Transfer of hydrogen, e.g. alcohol dehydrogenase.
• Class 2. Transferase:
Transfer of groups other than hydrogen. e.g.
hexokinase).
• Class 3. Hydrolases:
Cleave bond; adds water, e.g. acetyl choline esterase.
5
• Class 4. Lyases:
Cleave without adding water, e.g. aldolase.
• Class 5. Isomerases:
Intramolecular transfers. Example, triose phosphate
isomerase.
• Class 6. Ligases:
ATP dependent condensation of two molecules, e.g.
acetyl CoA carboxylase.
6
Holoenzymes
• Some enzymes require molecules other than
proteins for enzymatic activity.
• The term holoenzyme refers to the active enzyme
with its nonprotein component.
• The term apoenzyme is inactive enzyme without
its nonprotein part.
• If the nonprotein part is a metal ion such as Zn
2+ or Fe2+, it is called a cofactor.
• If it is a small organic molecule, it is termed a
coenzyme.
7
8
• Coenzymes that only transiently associate with
the enzyme are called co-substrates. It acts by
donating or accepting hydrogen atoms or
electrons (NAD+, NADP, FAD and FMN).
• Or transferring groups other than hydrogen.
• If the coenzyme is permanently associated with
the enzyme and returned to its original form, it is
called a prosthetic group as FAD.
• Coenzymes frequently are derived from vitamins.
Example, NAD+ contains niacin, FAD contains
riboflavin.
• Also ATP is an example of coenzyme.
9
Salient features of coenzymes:
• Coenzymes are heat stable. They are low-molecular
weight substances.
• The coenzymes combine loosely with the enzyme
molecules and so, the coenzyme can be separated
easily by dialysis.
• When the reaction is completed, the coenzyme is
released from the apo-enzyme, and goes to some
other reaction site.
10
Function of coenzyme
• The coenzyme is essential for the
biological activity of the enzyme.
• A coenzyme is a low molecular weight
organic substance, without which the
enzyme cannot exhibit any reaction.
• One molecule of the coenzyme is able to
convert a large number of substrate
molecules with the help of enzyme.
11
Nicotinamide Adenine Dincleotide
(NAD+)
• This is a coenzyme synthesized from
Nicotinamide, a member of vitamin B complex.
• The structure of NAD+ could be written as:
Nicotinamide-Ribose-P-P-Ribose-Adenine
• The reversible reaction of lactate to pyruvate is
catalyzed by the enzyme lactate
dehydrogenase, but the actual transfer of
hydrogen is taking place on the coenzyme,
NAD+.
12
COO- COO-
I Lactate dehydrogenase I
CHOH ←-----------------------------------→ C=O
I NAD+ → NADH I
CH3 CH3
Lactate
Pyruvate
13
Adinosine triphosphate (ATP):
• ATP is considered to be the energy currency in the
body.
• During the oxidation of food stuffs, energy is released,
a part of which is stored as chemical energy in the form
of ATP.
• In the ATP molecule, the second and third phosphate
bonds are 'high energy' bonds.
• For example;
Hexokinase
Glucose --------------------------------→ Glucose-6-
phosphate
ATP → ADP
14
Mode of action of enzymes
• There are few theories explaining the mechanism of
action of enzymes
1- Lowering of activation energy
• Presence of enzyme in the reaction decrease the
activation energy which is defined as the energy
required to convert all molecules in one mole of a
reacting substance from the ground state to the
transition state.
15
16
2- Michaelis-Menten theory
• This also called enzyme-substrate complex
theory.
• The enzyme (E) combines with the substrate
(S), to form an enzyme-substrate (ES)
complex, which immediately breaks down to
the enzyme and the product (P).
• E + S → E-S complex → E + P
17
18
Fischer's Template theory:-3
• The explanation is that substrate fits on the
enzyme, similar to lock and key. The key will
fit only to its own lock.
4- Koshland's induced fit theory
• substrate binds to a specific part of the
enzyme, this lead to conformational changes.
19
20
Active site or active center
• It is the area of the enzyme where catalysis occurs
(i.e. the reaction occur).
• The active site occupies only a small portion of the
whole enzyme.
• Generally active site is situated in a crevice or cleft
of the enzyme molecule.
• The amino acids or groups that directly participate
in making or breaking the bonds (present at the
active site) are called catalytic residues or catalytic
groups. As example Proteolytic enzymes having a
serine residue at the active center called serine
proteases.21
• The specific substrate bound to the active site.
• During binding, the catalytic group orient itself to
promote exact fitting of substrate to the active site.
22
23
Thermodynamics:
• From the standpoint of energy, the enzymatic
reactions are divided into three types:
1- Exergonic or Exothermic reaction
• In this reaction energy is released when the
reaction essentially goes to completion. This
reaction is generally irreversible.
• e.g. Urease enzyme
Urea → ammonia + CO2 + energy
• At equilibrium of this reaction, the substrate will be
only 0.5% and product will be 99.5%.
24
2- Isothermic reaction:
• In this reaction, the exchange of energy is
negligible and the reaction is easily reversible.
• e.g. Glycogen +Pi → Glucose-1-phosphate
• At equilibrium of this reaction, 77% glycogen will be
unutilized and 23% glucose-1-phosphate will be
formed.
25
3- Endergonic or Endothermic reaction
• Energy is consumed and external energy is to be
supplied for these reactions. In the body this is
usually accomplished by coupling the endergonic
reaction with an exergonic reaction.
• e.g. Hexokinase reaction
Glucose + ATP → Glucose-6-Phosphate + ADP
26
Factors influencing enzyme activity
1- Enzyme concentration:
• Velocity of reaction is increased proportionately with
the concentration of enzyme, when substrate
concentration is unlimited.
2- Substrate concentration:
• As substrate concentration is increased, the velocity is
also correspondingly increased in the initial phases; but
the curve flattens afterwards. The maximum velocity
thus obtained is called Vmax.
3- Effect of concentration of products:
• When product concentration is increased, the reaction
is slowed, stopped or even reversed.27
4- Effect of temperature:
• The velocity of enzyme reaction increases when
temperature of the medium is increased; reaches a
maximum and then falls.
• As temperature is increased, more molecules get
activation energy, or molecules are at increased rate of
motion. So their collision probabilities are increased
and so the reaction velocity is enhanced.
• But when temperature is more than 50°C, heat
denaturation and consequent loss of tertiary structure
of protein occurs. So activity of the enzyme decreased.
• Most human enzymes have the optimum temperature
around 37°C. Certain bacteria living in hot springs will
have enzymes with optimum temperature near 100°C.
28
5- Effect of pH:
• Each enzyme has an optimum pH, on both sides of
which the velocity will be drastically reduced.
• Usually enzymes have the optimum pH between 6
and 8.
• Some important exceptions are Pepsin (with
optimum pH 1-2), alkaline phosphatase (optimum
pH 9-10) and acid phosphatase (4-5).
29
Enzyme activation
Enzymes activated by different methods as:
• Presence of certain metallic ions, e.g. calcium
activate lipase.
• Conversion of an inactive proenzyme or zymogen
to the active enzyme. E.g. splitting of a single
peptide bond and removal of a small polypeptide
from trypsinogen, the active trypsin is formed.
• Covalent modification, in which activation of
enzyme occur by adding or removing groups
(breaking or making covalent bonds).
30
Enzyme inhibition
All the reactions in the body are
appropriately controlled. Control of
the whole pathway is achieved by
inhibition of such key enzymes or
regulatory enzymes.
31
1- Competitive inhibition:
• In this type, the inhibitor will be a structural analog
of the substrate. There will be similarity in three-
dimensional structure between substrate (S) and
inhibitor (I).
• The inhibitor molecules are competing with the
normal substrate molecules for attaching with the
active site of the enzyme.
• E + S → E-S → E + P
• E + I → E-I
32
• Since E-I (enzyme-inhibitor complex) can react only
to reform the enzyme and inhibitor, the number of
enzyme molecules available for E-S formation is
reduced.
• Competitive inhibition is usually reversible. Excess
substrate abolishes the inhibition. If substrate
concentration is enormously high when compared
to inhibitor, then the inhibition is reversed.
• For example, the succinate dehydrogenase reaction
is inhibited by malonate, which are structural
analogs of succinate.
33
Clinical significance:
• Pharmacological action of many drugs may be
explained by the principle of competitive inhibition.
As example:
• Sulphonamides are commonly employed
antibacterial agents. Bacteria synthesize folic acid
by combining PABA with pteroylglutamic acid. .
Bacteria wall is impermeable to folic acid. Sulpha
drugs, being structural analogs of PABA, will inhibit
the folic acid synthesis in bacteria, and then die.
The drug nontoxic to human cells, because human
beings cannot synthesizes folic acid.
34
Methotrexate is structural analog to folic
acid, and so can competitively inhibit
folate reductase enzyme. This is essential
for DNA synthesis and cell division.
Therefore, methotrexate is used as an
anticancer drug.
35
2- Noncompetitive inhibition
• A variety of poisons, such as iodoacetate, heavy
metal ions (silver, mercury) and oxidizing agents act
as irreversible noncompetitive inhibitors.
• The inhibitor usually binds to different domain on
the enzyme, other than the substrate binding site.
• Since these inhibitors have no structural
resemblance to the substrate, an increase in the
substrate concentration generally does not relieve
this inhibition.36
• Cyanide inhibits cytochrome oxidase. Fluoride
will remove magnesium ions and will inhibit
the enzyme, enolase, and consequently the
glycolysis.
• The inhibitor combines with the enzymes and
reaction becomes irreversible.
• The velocity of the reaction is reduced.
• Increasing substrate concentration will abolish
the competitive inhibition, but will not abolish
non-competitive inhibition.37
3- Allosteric regulation:
• Allosteric enzyme has one catalytic site where
the substrate binds and another separate
allosteric site where the modifier binds
(allo=other).
• Allosteric enzymes are utilized by the body for
regulating metabolic pathways. Such a
regulatory enzyme in a particular pathway is
called the key enzyme or rate limiting
enzyme.
38
39
Isoenzymes
• They are physically distinct forms of the same
enzyme activity. Multiple molecular form of
an enzyme is described as isoenzymes or
isozymes. They synthesized from various
tissues
• Ex. Lactate dehydrogenase has 5 forms.
• The study of isoenzymes is useful to
understand diseases of different organs.
40
Clinical enzymology
• Plasma contains many functional enzymes which
are actively secreted into plasma. For example,
enzymes of blood coagulation.
• On the other hand, there are a few non-functional
enzymes in plasma, which are coming out from cells
of various tissues due to normal wear and tear.
• Their normal levels in blood are very low, but are
drastically increased during cell death (necrosis) or
disease.
• Therefore, assays of these enzymes are very useful
in diagnosis of diseases.41
(LDH):DehydrogenaseLactate
Isoenzymes of LDH
• LDH enzyme is a tetramer with 4 subunits. But the
subunit may be either H (heart) or M (muscle)
polypeptide chains. These two are the products of 2
different genes.
• S0 5 combinations of H and M chains are possible;
H4, H3M, H2M2, M3H and M4 varieties, forming 5
isoenzymes. All these 5 forms are seen in all
persons.
42
• M4 form is seen in skeletal muscles; while H4 form
is seen in heart.
• Normally LDH-2 (H3M1) concentration in blood is
greater than LDH-1 (H4); but this pattern is reversed
in myocardial infarction; this is called flipped
pattern. The isoenzymes are usually separated by
cellulose acetate electrophoresis.
• In myocardial infarction, LDH activity is increased.
Within a few hours after the heart attack, the
enzyme level starts to increase, reaches a peak on
the 5th day, and reaches normal levels by 10-12
days.
43
(CK):KinaseCreatine
• Ck value in serum is increased in myocardial
infarction. The CK level starts to rise within 3 hours
of infarction.
• Therefore CK estimation is very useful to detect
early cases.
• The CK level is not increased in hemolysis or in
congestive cardiac failure; and therefore Ck has an
advantage over LDH.
44
CK and Muscle Diseases
• The level of CK in serum is very much elevated in
muscular dystrophies. The level is very high in the
early phases of the disease.
• CK level is highly elevated in crush injury, fracture
and acute cerebrovascular accidents.
• Estimation of total CK is employed in muscular
dystrophies and MB isoenzyme is estimated in
myocardial infarction.
45
Isoenzymes of CK
• CK is a dimer. The subunits are called B for brain and
M for muscle. Therefore, three isoenzymes are seen
in circulation.
• MM (CK3) is originating from skeletal muscles. MB
(CK2) is from heart and BB (CK1) is from brain.
• Hence, the detection of MB- isoenzyme is important
in myocardial infarction.
• The most sensitive and earlier marker of acute
myocardial infarction (AM) is either Troponin I or
Troponin T.
46
(ALT)transferaseaminoALanine
• In old literature, it was called as serum glutamate
pyruvate transaminase (SGPT). The enzyme needs
pyridoxal phosphate as coenzyme.
• Normal serum level of ALT for male is 13-35 U/L and for
female is 10-30 U/L.
• Very high values (100 to 1000 U/L) are seen in acute
hepatitis, either toxic or viral in origin.
• Both ALT and AST levels are increased in liver disease,
but ALT˃˃ AST. Rise in ALT levels may be noticed several
days before clinical such as jaundice is manifested.
• Moderate increase (25 to 100 U/L) may be seen in
chronic liver diseases such as cirrhosis, and
malignancy in liver.
47
Alkaline Phosphatase (ALP)
• ALP is a nonspecific enzyme which hydrolyses
aliphatic, aromatic or heterocyclic
compounds. The pH optimum for the enzyme
reaction is between 9 and 10.
• It is produced by osteoblasts of bone, and is
associated with the calcification process.
Normal serum value of ALP is 40-125 U/L.
• In children the upper level of normal value
may be more, because of the increased
osteoblastic activity in children.48
• Moderate increase (2-3 times) in ALP level is
seen in hepatic diseases such as infective
hepatitis, alcoholic hepatitis or hepatocellular
carcinoma.
• Very high levels of ALP (10-12 times of upper
limit) may be noticed in extrahepatic
obstruction (obstructive jaundice) caused by gall
stones or by pressure on bile duct by carcinoma
of head of pancreas or enlarged lymph nodes.
49
Enzyme patterns (profile) in diseases
I. Hepatic diseases
• Alanine amino transferase (ALT):
Marked increase in parenchymal diseases.
• Alkaline phosphatase (ALP):
Marked increase in obstructive liver disease.
50
II. Myocardial infarction
• Creatine kinase (CK-MB):
First enzyme to rise following infarction, CK-MB
isoenzyme is specific.
• Aspartate amino transferase (AST):
Rises after the rise in CK and return to normal in 4-5
days.
• Lactate dehydrogenase (LDH):
Last enzyme to rise. LDH-1 becomes more than 2
(Flipped pattern).51
III. Muscle diseases
• Creatine kinase (CK-MM):
Marked increase in muscle diseases. CK-MM
fraction is elevated.
IV. Bone diseases
• Alkaline phosphatase (ALP):
Marked elevation in osteoblastic bone
activity as in rickets. Heat labile bone.
52
V. Prostate cancer
• Prostate specific antigen (PSA):
Marker of prostate cancer. Mild increase in
benign prostate enlargement.
• Acid phosphatase (ACP):
Marker of prostate cancer. Metastatic bone
disease especially from a primary from
prostate. Inhibited by L tartrate.
53
THANKS
54

More Related Content

What's hot

Enzymes bph
Enzymes bphEnzymes bph
Enzymes bph
RaNa MB
 
ENZYMES
ENZYMESENZYMES
ENZYMES
YESANNA
 
Co enzymes
Co enzymesCo enzymes
Co enzymes
Pulkit Agarwal
 
CHEMISTRY OF ENZYMES
CHEMISTRY OF ENZYMESCHEMISTRY OF ENZYMES
CHEMISTRY OF ENZYMES
Shamim Akram
 
Enzymes classification of enzyme and -isoenzymes-1
Enzymes classification of enzyme and -isoenzymes-1Enzymes classification of enzyme and -isoenzymes-1
Enzymes classification of enzyme and -isoenzymes-1
Microbiology
 
Classification of enzymes and properties of enzymes
Classification of enzymes and properties of enzymesClassification of enzymes and properties of enzymes
Classification of enzymes and properties of enzymes
muti ullah
 
Enzyme
EnzymeEnzyme
Enzyme
Farhana Atia
 
Enzymology ii factors affecting enzyme activity
Enzymology ii factors affecting enzyme activityEnzymology ii factors affecting enzyme activity
Enzymology ii factors affecting enzyme activity
Hetal Doctor
 
Enzymes
EnzymesEnzymes
Enzymes
Nadine Attard
 
Section 5.5 How do cofactors work?
Section 5.5 How do cofactors work?Section 5.5 How do cofactors work?
Section 5.5 How do cofactors work?
Amo Oliverio
 
Cofactors, coenzymes and prosthetic group
Cofactors, coenzymes and prosthetic groupCofactors, coenzymes and prosthetic group
Cofactors, coenzymes and prosthetic group
Namrata Chhabra
 
#BIOCHEMISTRY#ENZYME
#BIOCHEMISTRY#ENZYME#BIOCHEMISTRY#ENZYME
#BIOCHEMISTRY#ENZYME
Sayali Powar
 
Enzymology
Enzymology Enzymology
Enzymology
Pave Medicine
 
Enzyme ppt
Enzyme pptEnzyme ppt
Enzyme ppt
Ibad khan
 
Enzymes & isoenzymes by Dr. Anurag Yadav
Enzymes & isoenzymes by Dr. Anurag YadavEnzymes & isoenzymes by Dr. Anurag Yadav
Enzymes & isoenzymes by Dr. Anurag Yadav
Dr Anurag Yadav
 
Chapter 5 enzymes
Chapter 5   enzymesChapter 5   enzymes
Chapter 5 enzymesJiapei Tan
 
Definitions and types of coenzymes
Definitions and types of coenzymesDefinitions and types of coenzymes
Definitions and types of coenzymes
JasmineJuliet
 

What's hot (19)

Enzymes bph
Enzymes bphEnzymes bph
Enzymes bph
 
Enzymes 1
Enzymes 1Enzymes 1
Enzymes 1
 
ENZYMES
ENZYMESENZYMES
ENZYMES
 
Co enzymes
Co enzymesCo enzymes
Co enzymes
 
CHEMISTRY OF ENZYMES
CHEMISTRY OF ENZYMESCHEMISTRY OF ENZYMES
CHEMISTRY OF ENZYMES
 
Enzymes classification of enzyme and -isoenzymes-1
Enzymes classification of enzyme and -isoenzymes-1Enzymes classification of enzyme and -isoenzymes-1
Enzymes classification of enzyme and -isoenzymes-1
 
Classification of enzymes and properties of enzymes
Classification of enzymes and properties of enzymesClassification of enzymes and properties of enzymes
Classification of enzymes and properties of enzymes
 
Enzyme
EnzymeEnzyme
Enzyme
 
Enzymology ii factors affecting enzyme activity
Enzymology ii factors affecting enzyme activityEnzymology ii factors affecting enzyme activity
Enzymology ii factors affecting enzyme activity
 
Powerpoint enzymes
Powerpoint enzymesPowerpoint enzymes
Powerpoint enzymes
 
Enzymes
EnzymesEnzymes
Enzymes
 
Section 5.5 How do cofactors work?
Section 5.5 How do cofactors work?Section 5.5 How do cofactors work?
Section 5.5 How do cofactors work?
 
Cofactors, coenzymes and prosthetic group
Cofactors, coenzymes and prosthetic groupCofactors, coenzymes and prosthetic group
Cofactors, coenzymes and prosthetic group
 
#BIOCHEMISTRY#ENZYME
#BIOCHEMISTRY#ENZYME#BIOCHEMISTRY#ENZYME
#BIOCHEMISTRY#ENZYME
 
Enzymology
Enzymology Enzymology
Enzymology
 
Enzyme ppt
Enzyme pptEnzyme ppt
Enzyme ppt
 
Enzymes & isoenzymes by Dr. Anurag Yadav
Enzymes & isoenzymes by Dr. Anurag YadavEnzymes & isoenzymes by Dr. Anurag Yadav
Enzymes & isoenzymes by Dr. Anurag Yadav
 
Chapter 5 enzymes
Chapter 5   enzymesChapter 5   enzymes
Chapter 5 enzymes
 
Definitions and types of coenzymes
Definitions and types of coenzymesDefinitions and types of coenzymes
Definitions and types of coenzymes
 

Similar to Lec4 level3-deenzymescoenzymescofactors-130202042833-phpapp01

Lec 4 level 3-de (enzymes, coenzymes, cofactors)
Lec 4  level 3-de (enzymes, coenzymes, cofactors)Lec 4  level 3-de (enzymes, coenzymes, cofactors)
Lec 4 level 3-de (enzymes, coenzymes, cofactors)dream10f
 
Lec4 level3-nuenzymes-130204053400-phpapp02
Lec4 level3-nuenzymes-130204053400-phpapp02Lec4 level3-nuenzymes-130204053400-phpapp02
Lec4 level3-nuenzymes-130204053400-phpapp02
Cleophas Rwemera
 
CHAPTER 6.pptx
CHAPTER 6.pptxCHAPTER 6.pptx
CHAPTER 6.pptx
Sayali Powar
 
Enzymes.pptx
Enzymes.pptxEnzymes.pptx
Enzymes.pptx
Vishnu988156
 
Enzymes and enzyme inhibition
Enzymes and enzyme inhibitionEnzymes and enzyme inhibition
Enzymes and enzyme inhibition
Prachi Pathak
 
Microbial metabolism
Microbial metabolismMicrobial metabolism
Microbial metabolism
NicoleRaineCabasa2
 
ENZYME BIOCHEMISTRY
ENZYME BIOCHEMISTRYENZYME BIOCHEMISTRY
ENZYME BIOCHEMISTRY
Naresh Panigrahi
 
JAndrew/ENZYMES.pptx
JAndrew/ENZYMES.pptxJAndrew/ENZYMES.pptx
JAndrew/ENZYMES.pptx
shakinadeiv1
 
2024_Chapter_4_Edited_Cellular_Metabolism_and_Metabolic_Disorders (4).pptx
2024_Chapter_4_Edited_Cellular_Metabolism_and_Metabolic_Disorders (4).pptx2024_Chapter_4_Edited_Cellular_Metabolism_and_Metabolic_Disorders (4).pptx
2024_Chapter_4_Edited_Cellular_Metabolism_and_Metabolic_Disorders (4).pptx
ErmiyasBeletew
 
Overview of enzyme
Overview of enzymeOverview of enzyme
Enzymes
Enzymes Enzymes
5. Biochemistry of enzymes edited 2024.pptx
5. Biochemistry of enzymes edited 2024.pptx5. Biochemistry of enzymes edited 2024.pptx
5. Biochemistry of enzymes edited 2024.pptx
mohammed959032
 
D. Pharm BIOCHEMISTRY AND CLINICAL PATHOLOGY Enzyme
D. Pharm BIOCHEMISTRY AND CLINICAL PATHOLOGY EnzymeD. Pharm BIOCHEMISTRY AND CLINICAL PATHOLOGY Enzyme
D. Pharm BIOCHEMISTRY AND CLINICAL PATHOLOGY Enzyme
Arun Kumar
 
Enzymes-.pdf
Enzymes-.pdfEnzymes-.pdf
Enzymes-.pdf
AlodiaPastorizo
 
Enzyme and Coenzyme
Enzyme and CoenzymeEnzyme and Coenzyme
Enzyme and Coenzyme
PotatoFries12
 
Enzymes
EnzymesEnzymes
Enzymes
ShaliniBarad
 
POINT- BIOCHEMISTRY SEM 2 ENZYMES UNIT 5.pptx
POINT- BIOCHEMISTRY SEM 2 ENZYMES UNIT 5.pptxPOINT- BIOCHEMISTRY SEM 2 ENZYMES UNIT 5.pptx
POINT- BIOCHEMISTRY SEM 2 ENZYMES UNIT 5.pptx
Sayali Powar
 

Similar to Lec4 level3-deenzymescoenzymescofactors-130202042833-phpapp01 (20)

Lec 4 level 3-de (enzymes, coenzymes, cofactors)
Lec 4  level 3-de (enzymes, coenzymes, cofactors)Lec 4  level 3-de (enzymes, coenzymes, cofactors)
Lec 4 level 3-de (enzymes, coenzymes, cofactors)
 
Lec4 level3-nuenzymes-130204053400-phpapp02
Lec4 level3-nuenzymes-130204053400-phpapp02Lec4 level3-nuenzymes-130204053400-phpapp02
Lec4 level3-nuenzymes-130204053400-phpapp02
 
CHAPTER 6.pptx
CHAPTER 6.pptxCHAPTER 6.pptx
CHAPTER 6.pptx
 
Enzymes.pptx
Enzymes.pptxEnzymes.pptx
Enzymes.pptx
 
Enzymes and enzyme inhibition
Enzymes and enzyme inhibitionEnzymes and enzyme inhibition
Enzymes and enzyme inhibition
 
Microbial metabolism
Microbial metabolismMicrobial metabolism
Microbial metabolism
 
ENZYME BIOCHEMISTRY
ENZYME BIOCHEMISTRYENZYME BIOCHEMISTRY
ENZYME BIOCHEMISTRY
 
51196538 enzymes chapter 3
51196538 enzymes chapter 351196538 enzymes chapter 3
51196538 enzymes chapter 3
 
JAndrew/ENZYMES.pptx
JAndrew/ENZYMES.pptxJAndrew/ENZYMES.pptx
JAndrew/ENZYMES.pptx
 
2024_Chapter_4_Edited_Cellular_Metabolism_and_Metabolic_Disorders (4).pptx
2024_Chapter_4_Edited_Cellular_Metabolism_and_Metabolic_Disorders (4).pptx2024_Chapter_4_Edited_Cellular_Metabolism_and_Metabolic_Disorders (4).pptx
2024_Chapter_4_Edited_Cellular_Metabolism_and_Metabolic_Disorders (4).pptx
 
Overview of enzyme
Overview of enzymeOverview of enzyme
Overview of enzyme
 
Enzymes
Enzymes Enzymes
Enzymes
 
5. Biochemistry of enzymes edited 2024.pptx
5. Biochemistry of enzymes edited 2024.pptx5. Biochemistry of enzymes edited 2024.pptx
5. Biochemistry of enzymes edited 2024.pptx
 
D. Pharm BIOCHEMISTRY AND CLINICAL PATHOLOGY Enzyme
D. Pharm BIOCHEMISTRY AND CLINICAL PATHOLOGY EnzymeD. Pharm BIOCHEMISTRY AND CLINICAL PATHOLOGY Enzyme
D. Pharm BIOCHEMISTRY AND CLINICAL PATHOLOGY Enzyme
 
Enzymes-.pdf
Enzymes-.pdfEnzymes-.pdf
Enzymes-.pdf
 
Enzyme and Coenzyme
Enzyme and CoenzymeEnzyme and Coenzyme
Enzyme and Coenzyme
 
Enzymes. classification. isoenzymes
Enzymes. classification. isoenzymesEnzymes. classification. isoenzymes
Enzymes. classification. isoenzymes
 
Enzymes
EnzymesEnzymes
Enzymes
 
POINT- BIOCHEMISTRY SEM 2 ENZYMES UNIT 5.pptx
POINT- BIOCHEMISTRY SEM 2 ENZYMES UNIT 5.pptxPOINT- BIOCHEMISTRY SEM 2 ENZYMES UNIT 5.pptx
POINT- BIOCHEMISTRY SEM 2 ENZYMES UNIT 5.pptx
 
Chapter 4 enzymes
Chapter 4 enzymesChapter 4 enzymes
Chapter 4 enzymes
 

More from Cleophas Rwemera

Chapter003 150907175411-lva1-app6891
Chapter003 150907175411-lva1-app6891Chapter003 150907175411-lva1-app6891
Chapter003 150907175411-lva1-app6891
Cleophas Rwemera
 
Chapter002 150831173907-lva1-app6892
Chapter002 150831173907-lva1-app6892Chapter002 150831173907-lva1-app6892
Chapter002 150831173907-lva1-app6892
Cleophas Rwemera
 
Chapter001 150823230128-lva1-app6892
Chapter001 150823230128-lva1-app6892Chapter001 150823230128-lva1-app6892
Chapter001 150823230128-lva1-app6892
Cleophas Rwemera
 
Chapter25 cancer-140105085413-phpapp01
Chapter25 cancer-140105085413-phpapp01Chapter25 cancer-140105085413-phpapp01
Chapter25 cancer-140105085413-phpapp01
Cleophas Rwemera
 
Chapter24 immunology-140105101108-phpapp02
Chapter24 immunology-140105101108-phpapp02Chapter24 immunology-140105101108-phpapp02
Chapter24 immunology-140105101108-phpapp02
Cleophas Rwemera
 
Chapter23 nervecells-140105100942-phpapp02
Chapter23 nervecells-140105100942-phpapp02Chapter23 nervecells-140105100942-phpapp02
Chapter23 nervecells-140105100942-phpapp02
Cleophas Rwemera
 
Chapter22 themolecularcellbiologyofdevelopment-140105100412-phpapp02
Chapter22 themolecularcellbiologyofdevelopment-140105100412-phpapp02Chapter22 themolecularcellbiologyofdevelopment-140105100412-phpapp02
Chapter22 themolecularcellbiologyofdevelopment-140105100412-phpapp02
Cleophas Rwemera
 
Chapter21 cellbirthlineageanddeath-140105095914-phpapp02
Chapter21 cellbirthlineageanddeath-140105095914-phpapp02Chapter21 cellbirthlineageanddeath-140105095914-phpapp02
Chapter21 cellbirthlineageanddeath-140105095914-phpapp02
Cleophas Rwemera
 
Chapter20 regulatingtheeukaryoticcellcycle-140105095738-phpapp01
Chapter20 regulatingtheeukaryoticcellcycle-140105095738-phpapp01Chapter20 regulatingtheeukaryoticcellcycle-140105095738-phpapp01
Chapter20 regulatingtheeukaryoticcellcycle-140105095738-phpapp01
Cleophas Rwemera
 
Chapter19 integratingcellsintotissues-140105095535-phpapp02
Chapter19 integratingcellsintotissues-140105095535-phpapp02Chapter19 integratingcellsintotissues-140105095535-phpapp02
Chapter19 integratingcellsintotissues-140105095535-phpapp02
Cleophas Rwemera
 
Chapter18 cellorganizationandmovementiimicrotubulesandintermediatefilaments-1...
Chapter18 cellorganizationandmovementiimicrotubulesandintermediatefilaments-1...Chapter18 cellorganizationandmovementiimicrotubulesandintermediatefilaments-1...
Chapter18 cellorganizationandmovementiimicrotubulesandintermediatefilaments-1...
Cleophas Rwemera
 
Chapter17 cellorganizationandmovementimicrofilaments-140105094810-phpapp02
Chapter17 cellorganizationandmovementimicrofilaments-140105094810-phpapp02Chapter17 cellorganizationandmovementimicrofilaments-140105094810-phpapp02
Chapter17 cellorganizationandmovementimicrofilaments-140105094810-phpapp02
Cleophas Rwemera
 
Chapter16 cellsignalingiisignalingpathwaysthatcontrolgeneactivity-14010509451...
Chapter16 cellsignalingiisignalingpathwaysthatcontrolgeneactivity-14010509451...Chapter16 cellsignalingiisignalingpathwaysthatcontrolgeneactivity-14010509451...
Chapter16 cellsignalingiisignalingpathwaysthatcontrolgeneactivity-14010509451...
Cleophas Rwemera
 
Chapter15 cellsignalingisignaltransductionandshort-termcellularresponses-1401...
Chapter15 cellsignalingisignaltransductionandshort-termcellularresponses-1401...Chapter15 cellsignalingisignaltransductionandshort-termcellularresponses-1401...
Chapter15 cellsignalingisignaltransductionandshort-termcellularresponses-1401...
Cleophas Rwemera
 
Chapter14 vesiculartrafficsecretionandendocytosis-140105094215-phpapp01
Chapter14 vesiculartrafficsecretionandendocytosis-140105094215-phpapp01Chapter14 vesiculartrafficsecretionandendocytosis-140105094215-phpapp01
Chapter14 vesiculartrafficsecretionandendocytosis-140105094215-phpapp01
Cleophas Rwemera
 
Chapter13 movingproteinsintomembranesandorganelles-140105094005-phpapp01
Chapter13 movingproteinsintomembranesandorganelles-140105094005-phpapp01Chapter13 movingproteinsintomembranesandorganelles-140105094005-phpapp01
Chapter13 movingproteinsintomembranesandorganelles-140105094005-phpapp01
Cleophas Rwemera
 
Chapter12 cellularenergetics-140105093734-phpapp01
Chapter12 cellularenergetics-140105093734-phpapp01Chapter12 cellularenergetics-140105093734-phpapp01
Chapter12 cellularenergetics-140105093734-phpapp01
Cleophas Rwemera
 
Chapter11 transmembranetransportofionsandsmallmolecules-140105092904-phpapp02
Chapter11 transmembranetransportofionsandsmallmolecules-140105092904-phpapp02Chapter11 transmembranetransportofionsandsmallmolecules-140105092904-phpapp02
Chapter11 transmembranetransportofionsandsmallmolecules-140105092904-phpapp02
Cleophas Rwemera
 
Chapter10 biomembranestructure-140105093829-phpapp02
Chapter10 biomembranestructure-140105093829-phpapp02Chapter10 biomembranestructure-140105093829-phpapp02
Chapter10 biomembranestructure-140105093829-phpapp02
Cleophas Rwemera
 
Chapter9 visualizingfractionatingandculturingcells-140105092245-phpapp01
Chapter9 visualizingfractionatingandculturingcells-140105092245-phpapp01Chapter9 visualizingfractionatingandculturingcells-140105092245-phpapp01
Chapter9 visualizingfractionatingandculturingcells-140105092245-phpapp01
Cleophas Rwemera
 

More from Cleophas Rwemera (20)

Chapter003 150907175411-lva1-app6891
Chapter003 150907175411-lva1-app6891Chapter003 150907175411-lva1-app6891
Chapter003 150907175411-lva1-app6891
 
Chapter002 150831173907-lva1-app6892
Chapter002 150831173907-lva1-app6892Chapter002 150831173907-lva1-app6892
Chapter002 150831173907-lva1-app6892
 
Chapter001 150823230128-lva1-app6892
Chapter001 150823230128-lva1-app6892Chapter001 150823230128-lva1-app6892
Chapter001 150823230128-lva1-app6892
 
Chapter25 cancer-140105085413-phpapp01
Chapter25 cancer-140105085413-phpapp01Chapter25 cancer-140105085413-phpapp01
Chapter25 cancer-140105085413-phpapp01
 
Chapter24 immunology-140105101108-phpapp02
Chapter24 immunology-140105101108-phpapp02Chapter24 immunology-140105101108-phpapp02
Chapter24 immunology-140105101108-phpapp02
 
Chapter23 nervecells-140105100942-phpapp02
Chapter23 nervecells-140105100942-phpapp02Chapter23 nervecells-140105100942-phpapp02
Chapter23 nervecells-140105100942-phpapp02
 
Chapter22 themolecularcellbiologyofdevelopment-140105100412-phpapp02
Chapter22 themolecularcellbiologyofdevelopment-140105100412-phpapp02Chapter22 themolecularcellbiologyofdevelopment-140105100412-phpapp02
Chapter22 themolecularcellbiologyofdevelopment-140105100412-phpapp02
 
Chapter21 cellbirthlineageanddeath-140105095914-phpapp02
Chapter21 cellbirthlineageanddeath-140105095914-phpapp02Chapter21 cellbirthlineageanddeath-140105095914-phpapp02
Chapter21 cellbirthlineageanddeath-140105095914-phpapp02
 
Chapter20 regulatingtheeukaryoticcellcycle-140105095738-phpapp01
Chapter20 regulatingtheeukaryoticcellcycle-140105095738-phpapp01Chapter20 regulatingtheeukaryoticcellcycle-140105095738-phpapp01
Chapter20 regulatingtheeukaryoticcellcycle-140105095738-phpapp01
 
Chapter19 integratingcellsintotissues-140105095535-phpapp02
Chapter19 integratingcellsintotissues-140105095535-phpapp02Chapter19 integratingcellsintotissues-140105095535-phpapp02
Chapter19 integratingcellsintotissues-140105095535-phpapp02
 
Chapter18 cellorganizationandmovementiimicrotubulesandintermediatefilaments-1...
Chapter18 cellorganizationandmovementiimicrotubulesandintermediatefilaments-1...Chapter18 cellorganizationandmovementiimicrotubulesandintermediatefilaments-1...
Chapter18 cellorganizationandmovementiimicrotubulesandintermediatefilaments-1...
 
Chapter17 cellorganizationandmovementimicrofilaments-140105094810-phpapp02
Chapter17 cellorganizationandmovementimicrofilaments-140105094810-phpapp02Chapter17 cellorganizationandmovementimicrofilaments-140105094810-phpapp02
Chapter17 cellorganizationandmovementimicrofilaments-140105094810-phpapp02
 
Chapter16 cellsignalingiisignalingpathwaysthatcontrolgeneactivity-14010509451...
Chapter16 cellsignalingiisignalingpathwaysthatcontrolgeneactivity-14010509451...Chapter16 cellsignalingiisignalingpathwaysthatcontrolgeneactivity-14010509451...
Chapter16 cellsignalingiisignalingpathwaysthatcontrolgeneactivity-14010509451...
 
Chapter15 cellsignalingisignaltransductionandshort-termcellularresponses-1401...
Chapter15 cellsignalingisignaltransductionandshort-termcellularresponses-1401...Chapter15 cellsignalingisignaltransductionandshort-termcellularresponses-1401...
Chapter15 cellsignalingisignaltransductionandshort-termcellularresponses-1401...
 
Chapter14 vesiculartrafficsecretionandendocytosis-140105094215-phpapp01
Chapter14 vesiculartrafficsecretionandendocytosis-140105094215-phpapp01Chapter14 vesiculartrafficsecretionandendocytosis-140105094215-phpapp01
Chapter14 vesiculartrafficsecretionandendocytosis-140105094215-phpapp01
 
Chapter13 movingproteinsintomembranesandorganelles-140105094005-phpapp01
Chapter13 movingproteinsintomembranesandorganelles-140105094005-phpapp01Chapter13 movingproteinsintomembranesandorganelles-140105094005-phpapp01
Chapter13 movingproteinsintomembranesandorganelles-140105094005-phpapp01
 
Chapter12 cellularenergetics-140105093734-phpapp01
Chapter12 cellularenergetics-140105093734-phpapp01Chapter12 cellularenergetics-140105093734-phpapp01
Chapter12 cellularenergetics-140105093734-phpapp01
 
Chapter11 transmembranetransportofionsandsmallmolecules-140105092904-phpapp02
Chapter11 transmembranetransportofionsandsmallmolecules-140105092904-phpapp02Chapter11 transmembranetransportofionsandsmallmolecules-140105092904-phpapp02
Chapter11 transmembranetransportofionsandsmallmolecules-140105092904-phpapp02
 
Chapter10 biomembranestructure-140105093829-phpapp02
Chapter10 biomembranestructure-140105093829-phpapp02Chapter10 biomembranestructure-140105093829-phpapp02
Chapter10 biomembranestructure-140105093829-phpapp02
 
Chapter9 visualizingfractionatingandculturingcells-140105092245-phpapp01
Chapter9 visualizingfractionatingandculturingcells-140105092245-phpapp01Chapter9 visualizingfractionatingandculturingcells-140105092245-phpapp01
Chapter9 visualizingfractionatingandculturingcells-140105092245-phpapp01
 

Recently uploaded

BÀI TẬP BỔ TRỢ TIẾNG ANH GLOBAL SUCCESS LỚP 3 - CẢ NĂM (CÓ FILE NGHE VÀ ĐÁP Á...
BÀI TẬP BỔ TRỢ TIẾNG ANH GLOBAL SUCCESS LỚP 3 - CẢ NĂM (CÓ FILE NGHE VÀ ĐÁP Á...BÀI TẬP BỔ TRỢ TIẾNG ANH GLOBAL SUCCESS LỚP 3 - CẢ NĂM (CÓ FILE NGHE VÀ ĐÁP Á...
BÀI TẬP BỔ TRỢ TIẾNG ANH GLOBAL SUCCESS LỚP 3 - CẢ NĂM (CÓ FILE NGHE VÀ ĐÁP Á...
Nguyen Thanh Tu Collection
 
Language Across the Curriculm LAC B.Ed.
Language Across the  Curriculm LAC B.Ed.Language Across the  Curriculm LAC B.Ed.
Language Across the Curriculm LAC B.Ed.
Atul Kumar Singh
 
Overview on Edible Vaccine: Pros & Cons with Mechanism
Overview on Edible Vaccine: Pros & Cons with MechanismOverview on Edible Vaccine: Pros & Cons with Mechanism
Overview on Edible Vaccine: Pros & Cons with Mechanism
DeeptiGupta154
 
June 3, 2024 Anti-Semitism Letter Sent to MIT President Kornbluth and MIT Cor...
June 3, 2024 Anti-Semitism Letter Sent to MIT President Kornbluth and MIT Cor...June 3, 2024 Anti-Semitism Letter Sent to MIT President Kornbluth and MIT Cor...
June 3, 2024 Anti-Semitism Letter Sent to MIT President Kornbluth and MIT Cor...
Levi Shapiro
 
Palestine last event orientationfvgnh .pptx
Palestine last event orientationfvgnh .pptxPalestine last event orientationfvgnh .pptx
Palestine last event orientationfvgnh .pptx
RaedMohamed3
 
How to Make a Field invisible in Odoo 17
How to Make a Field invisible in Odoo 17How to Make a Field invisible in Odoo 17
How to Make a Field invisible in Odoo 17
Celine George
 
Guidance_and_Counselling.pdf B.Ed. 4th Semester
Guidance_and_Counselling.pdf B.Ed. 4th SemesterGuidance_and_Counselling.pdf B.Ed. 4th Semester
Guidance_and_Counselling.pdf B.Ed. 4th Semester
Atul Kumar Singh
 
Synthetic Fiber Construction in lab .pptx
Synthetic Fiber Construction in lab .pptxSynthetic Fiber Construction in lab .pptx
Synthetic Fiber Construction in lab .pptx
Pavel ( NSTU)
 
1.4 modern child centered education - mahatma gandhi-2.pptx
1.4 modern child centered education - mahatma gandhi-2.pptx1.4 modern child centered education - mahatma gandhi-2.pptx
1.4 modern child centered education - mahatma gandhi-2.pptx
JosvitaDsouza2
 
Welcome to TechSoup New Member Orientation and Q&A (May 2024).pdf
Welcome to TechSoup   New Member Orientation and Q&A (May 2024).pdfWelcome to TechSoup   New Member Orientation and Q&A (May 2024).pdf
Welcome to TechSoup New Member Orientation and Q&A (May 2024).pdf
TechSoup
 
The basics of sentences session 5pptx.pptx
The basics of sentences session 5pptx.pptxThe basics of sentences session 5pptx.pptx
The basics of sentences session 5pptx.pptx
heathfieldcps1
 
Digital Tools and AI for Teaching Learning and Research
Digital Tools and AI for Teaching Learning and ResearchDigital Tools and AI for Teaching Learning and Research
Digital Tools and AI for Teaching Learning and Research
Vikramjit Singh
 
The geography of Taylor Swift - some ideas
The geography of Taylor Swift - some ideasThe geography of Taylor Swift - some ideas
The geography of Taylor Swift - some ideas
GeoBlogs
 
"Protectable subject matters, Protection in biotechnology, Protection of othe...
"Protectable subject matters, Protection in biotechnology, Protection of othe..."Protectable subject matters, Protection in biotechnology, Protection of othe...
"Protectable subject matters, Protection in biotechnology, Protection of othe...
SACHIN R KONDAGURI
 
Introduction to AI for Nonprofits with Tapp Network
Introduction to AI for Nonprofits with Tapp NetworkIntroduction to AI for Nonprofits with Tapp Network
Introduction to AI for Nonprofits with Tapp Network
TechSoup
 
Acetabularia Information For Class 9 .docx
Acetabularia Information For Class 9  .docxAcetabularia Information For Class 9  .docx
Acetabularia Information For Class 9 .docx
vaibhavrinwa19
 
Chapter 3 - Islamic Banking Products and Services.pptx
Chapter 3 - Islamic Banking Products and Services.pptxChapter 3 - Islamic Banking Products and Services.pptx
Chapter 3 - Islamic Banking Products and Services.pptx
Mohd Adib Abd Muin, Senior Lecturer at Universiti Utara Malaysia
 
special B.ed 2nd year old paper_20240531.pdf
special B.ed 2nd year old paper_20240531.pdfspecial B.ed 2nd year old paper_20240531.pdf
special B.ed 2nd year old paper_20240531.pdf
Special education needs
 
Model Attribute Check Company Auto Property
Model Attribute  Check Company Auto PropertyModel Attribute  Check Company Auto Property
Model Attribute Check Company Auto Property
Celine George
 
CLASS 11 CBSE B.St Project AIDS TO TRADE - INSURANCE
CLASS 11 CBSE B.St Project AIDS TO TRADE - INSURANCECLASS 11 CBSE B.St Project AIDS TO TRADE - INSURANCE
CLASS 11 CBSE B.St Project AIDS TO TRADE - INSURANCE
BhavyaRajput3
 

Recently uploaded (20)

BÀI TẬP BỔ TRỢ TIẾNG ANH GLOBAL SUCCESS LỚP 3 - CẢ NĂM (CÓ FILE NGHE VÀ ĐÁP Á...
BÀI TẬP BỔ TRỢ TIẾNG ANH GLOBAL SUCCESS LỚP 3 - CẢ NĂM (CÓ FILE NGHE VÀ ĐÁP Á...BÀI TẬP BỔ TRỢ TIẾNG ANH GLOBAL SUCCESS LỚP 3 - CẢ NĂM (CÓ FILE NGHE VÀ ĐÁP Á...
BÀI TẬP BỔ TRỢ TIẾNG ANH GLOBAL SUCCESS LỚP 3 - CẢ NĂM (CÓ FILE NGHE VÀ ĐÁP Á...
 
Language Across the Curriculm LAC B.Ed.
Language Across the  Curriculm LAC B.Ed.Language Across the  Curriculm LAC B.Ed.
Language Across the Curriculm LAC B.Ed.
 
Overview on Edible Vaccine: Pros & Cons with Mechanism
Overview on Edible Vaccine: Pros & Cons with MechanismOverview on Edible Vaccine: Pros & Cons with Mechanism
Overview on Edible Vaccine: Pros & Cons with Mechanism
 
June 3, 2024 Anti-Semitism Letter Sent to MIT President Kornbluth and MIT Cor...
June 3, 2024 Anti-Semitism Letter Sent to MIT President Kornbluth and MIT Cor...June 3, 2024 Anti-Semitism Letter Sent to MIT President Kornbluth and MIT Cor...
June 3, 2024 Anti-Semitism Letter Sent to MIT President Kornbluth and MIT Cor...
 
Palestine last event orientationfvgnh .pptx
Palestine last event orientationfvgnh .pptxPalestine last event orientationfvgnh .pptx
Palestine last event orientationfvgnh .pptx
 
How to Make a Field invisible in Odoo 17
How to Make a Field invisible in Odoo 17How to Make a Field invisible in Odoo 17
How to Make a Field invisible in Odoo 17
 
Guidance_and_Counselling.pdf B.Ed. 4th Semester
Guidance_and_Counselling.pdf B.Ed. 4th SemesterGuidance_and_Counselling.pdf B.Ed. 4th Semester
Guidance_and_Counselling.pdf B.Ed. 4th Semester
 
Synthetic Fiber Construction in lab .pptx
Synthetic Fiber Construction in lab .pptxSynthetic Fiber Construction in lab .pptx
Synthetic Fiber Construction in lab .pptx
 
1.4 modern child centered education - mahatma gandhi-2.pptx
1.4 modern child centered education - mahatma gandhi-2.pptx1.4 modern child centered education - mahatma gandhi-2.pptx
1.4 modern child centered education - mahatma gandhi-2.pptx
 
Welcome to TechSoup New Member Orientation and Q&A (May 2024).pdf
Welcome to TechSoup   New Member Orientation and Q&A (May 2024).pdfWelcome to TechSoup   New Member Orientation and Q&A (May 2024).pdf
Welcome to TechSoup New Member Orientation and Q&A (May 2024).pdf
 
The basics of sentences session 5pptx.pptx
The basics of sentences session 5pptx.pptxThe basics of sentences session 5pptx.pptx
The basics of sentences session 5pptx.pptx
 
Digital Tools and AI for Teaching Learning and Research
Digital Tools and AI for Teaching Learning and ResearchDigital Tools and AI for Teaching Learning and Research
Digital Tools and AI for Teaching Learning and Research
 
The geography of Taylor Swift - some ideas
The geography of Taylor Swift - some ideasThe geography of Taylor Swift - some ideas
The geography of Taylor Swift - some ideas
 
"Protectable subject matters, Protection in biotechnology, Protection of othe...
"Protectable subject matters, Protection in biotechnology, Protection of othe..."Protectable subject matters, Protection in biotechnology, Protection of othe...
"Protectable subject matters, Protection in biotechnology, Protection of othe...
 
Introduction to AI for Nonprofits with Tapp Network
Introduction to AI for Nonprofits with Tapp NetworkIntroduction to AI for Nonprofits with Tapp Network
Introduction to AI for Nonprofits with Tapp Network
 
Acetabularia Information For Class 9 .docx
Acetabularia Information For Class 9  .docxAcetabularia Information For Class 9  .docx
Acetabularia Information For Class 9 .docx
 
Chapter 3 - Islamic Banking Products and Services.pptx
Chapter 3 - Islamic Banking Products and Services.pptxChapter 3 - Islamic Banking Products and Services.pptx
Chapter 3 - Islamic Banking Products and Services.pptx
 
special B.ed 2nd year old paper_20240531.pdf
special B.ed 2nd year old paper_20240531.pdfspecial B.ed 2nd year old paper_20240531.pdf
special B.ed 2nd year old paper_20240531.pdf
 
Model Attribute Check Company Auto Property
Model Attribute  Check Company Auto PropertyModel Attribute  Check Company Auto Property
Model Attribute Check Company Auto Property
 
CLASS 11 CBSE B.St Project AIDS TO TRADE - INSURANCE
CLASS 11 CBSE B.St Project AIDS TO TRADE - INSURANCECLASS 11 CBSE B.St Project AIDS TO TRADE - INSURANCE
CLASS 11 CBSE B.St Project AIDS TO TRADE - INSURANCE
 

Lec4 level3-deenzymescoenzymescofactors-130202042833-phpapp01

  • 1. Dental Biochemistry 1- (4) Enzymes, coenzymes, cofactors 1
  • 2. Enzymes • Almost all enzymes are proteins. • Enzymes follow the physical and chemical reactions of proteins. • They are heat labile, soluble in water, precipitated by protein precipitating reagents (ammonium sulfate or trichloroacetic acid) and contain 16% weight as nitrogen. 2
  • 3. Enzymes are biocatalysts • Catalysts are substances which accelerate the rate of chemical reactions, but do not change the equilibrium. • Lack of enzymes will lead to block in metabolic pathways causing inborn errors of metabolism. • The substance upon which an enzyme acts, is called the substrate. • The enzyme will convert the substrate into the product or products.3
  • 4. Nomenclature of enzymes • Early workers gave whimsical names such as Pepsin, Trypsin, Chymotrypsin, ….etc. • Later workers gave the trivial names for some enzymes named by adding the suffix "ase" to the substrate, as example, enzyme Lactase acts on the substrate lactose. • But there may be more than one enzyme acting on the same substrate.4
  • 5. Classification of enzymes According to its function • Class 1. Oxidoreductase: Transfer of hydrogen, e.g. alcohol dehydrogenase. • Class 2. Transferase: Transfer of groups other than hydrogen. e.g. hexokinase). • Class 3. Hydrolases: Cleave bond; adds water, e.g. acetyl choline esterase. 5
  • 6. • Class 4. Lyases: Cleave without adding water, e.g. aldolase. • Class 5. Isomerases: Intramolecular transfers. Example, triose phosphate isomerase. • Class 6. Ligases: ATP dependent condensation of two molecules, e.g. acetyl CoA carboxylase. 6
  • 7. Holoenzymes • Some enzymes require molecules other than proteins for enzymatic activity. • The term holoenzyme refers to the active enzyme with its nonprotein component. • The term apoenzyme is inactive enzyme without its nonprotein part. • If the nonprotein part is a metal ion such as Zn 2+ or Fe2+, it is called a cofactor. • If it is a small organic molecule, it is termed a coenzyme. 7
  • 8. 8
  • 9. • Coenzymes that only transiently associate with the enzyme are called co-substrates. It acts by donating or accepting hydrogen atoms or electrons (NAD+, NADP, FAD and FMN). • Or transferring groups other than hydrogen. • If the coenzyme is permanently associated with the enzyme and returned to its original form, it is called a prosthetic group as FAD. • Coenzymes frequently are derived from vitamins. Example, NAD+ contains niacin, FAD contains riboflavin. • Also ATP is an example of coenzyme. 9
  • 10. Salient features of coenzymes: • Coenzymes are heat stable. They are low-molecular weight substances. • The coenzymes combine loosely with the enzyme molecules and so, the coenzyme can be separated easily by dialysis. • When the reaction is completed, the coenzyme is released from the apo-enzyme, and goes to some other reaction site. 10
  • 11. Function of coenzyme • The coenzyme is essential for the biological activity of the enzyme. • A coenzyme is a low molecular weight organic substance, without which the enzyme cannot exhibit any reaction. • One molecule of the coenzyme is able to convert a large number of substrate molecules with the help of enzyme. 11
  • 12. Nicotinamide Adenine Dincleotide (NAD+) • This is a coenzyme synthesized from Nicotinamide, a member of vitamin B complex. • The structure of NAD+ could be written as: Nicotinamide-Ribose-P-P-Ribose-Adenine • The reversible reaction of lactate to pyruvate is catalyzed by the enzyme lactate dehydrogenase, but the actual transfer of hydrogen is taking place on the coenzyme, NAD+. 12
  • 13. COO- COO- I Lactate dehydrogenase I CHOH ←-----------------------------------→ C=O I NAD+ → NADH I CH3 CH3 Lactate Pyruvate 13
  • 14. Adinosine triphosphate (ATP): • ATP is considered to be the energy currency in the body. • During the oxidation of food stuffs, energy is released, a part of which is stored as chemical energy in the form of ATP. • In the ATP molecule, the second and third phosphate bonds are 'high energy' bonds. • For example; Hexokinase Glucose --------------------------------→ Glucose-6- phosphate ATP → ADP 14
  • 15. Mode of action of enzymes • There are few theories explaining the mechanism of action of enzymes 1- Lowering of activation energy • Presence of enzyme in the reaction decrease the activation energy which is defined as the energy required to convert all molecules in one mole of a reacting substance from the ground state to the transition state. 15
  • 16. 16
  • 17. 2- Michaelis-Menten theory • This also called enzyme-substrate complex theory. • The enzyme (E) combines with the substrate (S), to form an enzyme-substrate (ES) complex, which immediately breaks down to the enzyme and the product (P). • E + S → E-S complex → E + P 17
  • 18. 18
  • 19. Fischer's Template theory:-3 • The explanation is that substrate fits on the enzyme, similar to lock and key. The key will fit only to its own lock. 4- Koshland's induced fit theory • substrate binds to a specific part of the enzyme, this lead to conformational changes. 19
  • 20. 20
  • 21. Active site or active center • It is the area of the enzyme where catalysis occurs (i.e. the reaction occur). • The active site occupies only a small portion of the whole enzyme. • Generally active site is situated in a crevice or cleft of the enzyme molecule. • The amino acids or groups that directly participate in making or breaking the bonds (present at the active site) are called catalytic residues or catalytic groups. As example Proteolytic enzymes having a serine residue at the active center called serine proteases.21
  • 22. • The specific substrate bound to the active site. • During binding, the catalytic group orient itself to promote exact fitting of substrate to the active site. 22
  • 23. 23
  • 24. Thermodynamics: • From the standpoint of energy, the enzymatic reactions are divided into three types: 1- Exergonic or Exothermic reaction • In this reaction energy is released when the reaction essentially goes to completion. This reaction is generally irreversible. • e.g. Urease enzyme Urea → ammonia + CO2 + energy • At equilibrium of this reaction, the substrate will be only 0.5% and product will be 99.5%. 24
  • 25. 2- Isothermic reaction: • In this reaction, the exchange of energy is negligible and the reaction is easily reversible. • e.g. Glycogen +Pi → Glucose-1-phosphate • At equilibrium of this reaction, 77% glycogen will be unutilized and 23% glucose-1-phosphate will be formed. 25
  • 26. 3- Endergonic or Endothermic reaction • Energy is consumed and external energy is to be supplied for these reactions. In the body this is usually accomplished by coupling the endergonic reaction with an exergonic reaction. • e.g. Hexokinase reaction Glucose + ATP → Glucose-6-Phosphate + ADP 26
  • 27. Factors influencing enzyme activity 1- Enzyme concentration: • Velocity of reaction is increased proportionately with the concentration of enzyme, when substrate concentration is unlimited. 2- Substrate concentration: • As substrate concentration is increased, the velocity is also correspondingly increased in the initial phases; but the curve flattens afterwards. The maximum velocity thus obtained is called Vmax. 3- Effect of concentration of products: • When product concentration is increased, the reaction is slowed, stopped or even reversed.27
  • 28. 4- Effect of temperature: • The velocity of enzyme reaction increases when temperature of the medium is increased; reaches a maximum and then falls. • As temperature is increased, more molecules get activation energy, or molecules are at increased rate of motion. So their collision probabilities are increased and so the reaction velocity is enhanced. • But when temperature is more than 50°C, heat denaturation and consequent loss of tertiary structure of protein occurs. So activity of the enzyme decreased. • Most human enzymes have the optimum temperature around 37°C. Certain bacteria living in hot springs will have enzymes with optimum temperature near 100°C. 28
  • 29. 5- Effect of pH: • Each enzyme has an optimum pH, on both sides of which the velocity will be drastically reduced. • Usually enzymes have the optimum pH between 6 and 8. • Some important exceptions are Pepsin (with optimum pH 1-2), alkaline phosphatase (optimum pH 9-10) and acid phosphatase (4-5). 29
  • 30. Enzyme activation Enzymes activated by different methods as: • Presence of certain metallic ions, e.g. calcium activate lipase. • Conversion of an inactive proenzyme or zymogen to the active enzyme. E.g. splitting of a single peptide bond and removal of a small polypeptide from trypsinogen, the active trypsin is formed. • Covalent modification, in which activation of enzyme occur by adding or removing groups (breaking or making covalent bonds). 30
  • 31. Enzyme inhibition All the reactions in the body are appropriately controlled. Control of the whole pathway is achieved by inhibition of such key enzymes or regulatory enzymes. 31
  • 32. 1- Competitive inhibition: • In this type, the inhibitor will be a structural analog of the substrate. There will be similarity in three- dimensional structure between substrate (S) and inhibitor (I). • The inhibitor molecules are competing with the normal substrate molecules for attaching with the active site of the enzyme. • E + S → E-S → E + P • E + I → E-I 32
  • 33. • Since E-I (enzyme-inhibitor complex) can react only to reform the enzyme and inhibitor, the number of enzyme molecules available for E-S formation is reduced. • Competitive inhibition is usually reversible. Excess substrate abolishes the inhibition. If substrate concentration is enormously high when compared to inhibitor, then the inhibition is reversed. • For example, the succinate dehydrogenase reaction is inhibited by malonate, which are structural analogs of succinate. 33
  • 34. Clinical significance: • Pharmacological action of many drugs may be explained by the principle of competitive inhibition. As example: • Sulphonamides are commonly employed antibacterial agents. Bacteria synthesize folic acid by combining PABA with pteroylglutamic acid. . Bacteria wall is impermeable to folic acid. Sulpha drugs, being structural analogs of PABA, will inhibit the folic acid synthesis in bacteria, and then die. The drug nontoxic to human cells, because human beings cannot synthesizes folic acid. 34
  • 35. Methotrexate is structural analog to folic acid, and so can competitively inhibit folate reductase enzyme. This is essential for DNA synthesis and cell division. Therefore, methotrexate is used as an anticancer drug. 35
  • 36. 2- Noncompetitive inhibition • A variety of poisons, such as iodoacetate, heavy metal ions (silver, mercury) and oxidizing agents act as irreversible noncompetitive inhibitors. • The inhibitor usually binds to different domain on the enzyme, other than the substrate binding site. • Since these inhibitors have no structural resemblance to the substrate, an increase in the substrate concentration generally does not relieve this inhibition.36
  • 37. • Cyanide inhibits cytochrome oxidase. Fluoride will remove magnesium ions and will inhibit the enzyme, enolase, and consequently the glycolysis. • The inhibitor combines with the enzymes and reaction becomes irreversible. • The velocity of the reaction is reduced. • Increasing substrate concentration will abolish the competitive inhibition, but will not abolish non-competitive inhibition.37
  • 38. 3- Allosteric regulation: • Allosteric enzyme has one catalytic site where the substrate binds and another separate allosteric site where the modifier binds (allo=other). • Allosteric enzymes are utilized by the body for regulating metabolic pathways. Such a regulatory enzyme in a particular pathway is called the key enzyme or rate limiting enzyme. 38
  • 39. 39
  • 40. Isoenzymes • They are physically distinct forms of the same enzyme activity. Multiple molecular form of an enzyme is described as isoenzymes or isozymes. They synthesized from various tissues • Ex. Lactate dehydrogenase has 5 forms. • The study of isoenzymes is useful to understand diseases of different organs. 40
  • 41. Clinical enzymology • Plasma contains many functional enzymes which are actively secreted into plasma. For example, enzymes of blood coagulation. • On the other hand, there are a few non-functional enzymes in plasma, which are coming out from cells of various tissues due to normal wear and tear. • Their normal levels in blood are very low, but are drastically increased during cell death (necrosis) or disease. • Therefore, assays of these enzymes are very useful in diagnosis of diseases.41
  • 42. (LDH):DehydrogenaseLactate Isoenzymes of LDH • LDH enzyme is a tetramer with 4 subunits. But the subunit may be either H (heart) or M (muscle) polypeptide chains. These two are the products of 2 different genes. • S0 5 combinations of H and M chains are possible; H4, H3M, H2M2, M3H and M4 varieties, forming 5 isoenzymes. All these 5 forms are seen in all persons. 42
  • 43. • M4 form is seen in skeletal muscles; while H4 form is seen in heart. • Normally LDH-2 (H3M1) concentration in blood is greater than LDH-1 (H4); but this pattern is reversed in myocardial infarction; this is called flipped pattern. The isoenzymes are usually separated by cellulose acetate electrophoresis. • In myocardial infarction, LDH activity is increased. Within a few hours after the heart attack, the enzyme level starts to increase, reaches a peak on the 5th day, and reaches normal levels by 10-12 days. 43
  • 44. (CK):KinaseCreatine • Ck value in serum is increased in myocardial infarction. The CK level starts to rise within 3 hours of infarction. • Therefore CK estimation is very useful to detect early cases. • The CK level is not increased in hemolysis or in congestive cardiac failure; and therefore Ck has an advantage over LDH. 44
  • 45. CK and Muscle Diseases • The level of CK in serum is very much elevated in muscular dystrophies. The level is very high in the early phases of the disease. • CK level is highly elevated in crush injury, fracture and acute cerebrovascular accidents. • Estimation of total CK is employed in muscular dystrophies and MB isoenzyme is estimated in myocardial infarction. 45
  • 46. Isoenzymes of CK • CK is a dimer. The subunits are called B for brain and M for muscle. Therefore, three isoenzymes are seen in circulation. • MM (CK3) is originating from skeletal muscles. MB (CK2) is from heart and BB (CK1) is from brain. • Hence, the detection of MB- isoenzyme is important in myocardial infarction. • The most sensitive and earlier marker of acute myocardial infarction (AM) is either Troponin I or Troponin T. 46
  • 47. (ALT)transferaseaminoALanine • In old literature, it was called as serum glutamate pyruvate transaminase (SGPT). The enzyme needs pyridoxal phosphate as coenzyme. • Normal serum level of ALT for male is 13-35 U/L and for female is 10-30 U/L. • Very high values (100 to 1000 U/L) are seen in acute hepatitis, either toxic or viral in origin. • Both ALT and AST levels are increased in liver disease, but ALT˃˃ AST. Rise in ALT levels may be noticed several days before clinical such as jaundice is manifested. • Moderate increase (25 to 100 U/L) may be seen in chronic liver diseases such as cirrhosis, and malignancy in liver. 47
  • 48. Alkaline Phosphatase (ALP) • ALP is a nonspecific enzyme which hydrolyses aliphatic, aromatic or heterocyclic compounds. The pH optimum for the enzyme reaction is between 9 and 10. • It is produced by osteoblasts of bone, and is associated with the calcification process. Normal serum value of ALP is 40-125 U/L. • In children the upper level of normal value may be more, because of the increased osteoblastic activity in children.48
  • 49. • Moderate increase (2-3 times) in ALP level is seen in hepatic diseases such as infective hepatitis, alcoholic hepatitis or hepatocellular carcinoma. • Very high levels of ALP (10-12 times of upper limit) may be noticed in extrahepatic obstruction (obstructive jaundice) caused by gall stones or by pressure on bile duct by carcinoma of head of pancreas or enlarged lymph nodes. 49
  • 50. Enzyme patterns (profile) in diseases I. Hepatic diseases • Alanine amino transferase (ALT): Marked increase in parenchymal diseases. • Alkaline phosphatase (ALP): Marked increase in obstructive liver disease. 50
  • 51. II. Myocardial infarction • Creatine kinase (CK-MB): First enzyme to rise following infarction, CK-MB isoenzyme is specific. • Aspartate amino transferase (AST): Rises after the rise in CK and return to normal in 4-5 days. • Lactate dehydrogenase (LDH): Last enzyme to rise. LDH-1 becomes more than 2 (Flipped pattern).51
  • 52. III. Muscle diseases • Creatine kinase (CK-MM): Marked increase in muscle diseases. CK-MM fraction is elevated. IV. Bone diseases • Alkaline phosphatase (ALP): Marked elevation in osteoblastic bone activity as in rickets. Heat labile bone. 52
  • 53. V. Prostate cancer • Prostate specific antigen (PSA): Marker of prostate cancer. Mild increase in benign prostate enlargement. • Acid phosphatase (ACP): Marker of prostate cancer. Metastatic bone disease especially from a primary from prostate. Inhibited by L tartrate. 53